Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2561| Título : | Kainic acid does not modify the oral pharmacokinetics of carbamazepine in rats |
| Creador: | Pérez Guillé, Beatriz |
| Nivel de acceso: | Open access |
| Palabras clave : | Carbamazepina - farmacocinética - ratas Carbamazepina - farmacología - ratas Carbamazepina - administración & dosificación - ratas Carbamazepina - sangre - ratas Ácido Kaínico - farmacología - ratas Ácido Kaínico - farmacocinética - ratas Ácido Kaínico - administración & dosificación - ratas Carbamazepine - pharmacokinetics - rats Carbamazepine - pharmacology - rats Carbamazepine - administration & dosage - rats Carbamazepine - blood - rats Kainic Acid - pharmacology - rats Kainic Acid - pharmacokinetics - rats Kainic Acid - administration & dosage - rats amino acid receptor stimulating agent; anticonvulsive agent; carbamazepine; kainic acid; animal; area under the curve; article; drug interaction; half life time; male; rat; Wistar rat; Animals; Anticonvulsants; Area Under Curve; Carbamazepine; Drug Interactions; Excitatory Amino Acid Agonists; Half-Life; Kainic Acid; Male; Rats; Rats, Wistar |
| Descripción : | Carbamazepine (CBZ) is a widely used antiepileptic agent that frequently interacts with other drugs. Recently, it has been reported that CBZ is able to modify the disturbed sleep patterns induced by kainic acid in epileptics. As a pharmacokinetic-pharmacodynamic characterization in the same animal is not possible due to the stress induced by blood sampling, it is important to establish if kainic acid is able to modify the pharmacokinetics of CBZ. Two groups of seven rats were used in this study. Animals received an oral dose of 50 mg/kg of CBZ alone or with 10 mg/kg of kainic acid. Blood samples (0.1 mL) were obtained at selected times for 12 hr and stored frozen until analyzed by HPLC. Pharmacokinetic parameters were: Cmax 6.51 ± 1.32 and 6.63 ± 0.95 μg/mL, tmax 3.55 ± 0.98 and 1.82 ± 0.59 hr, AUC 66.61 ± 28.16 and 73.54 ± 15.35 μg.h/mL and t1/2 7.16 ± 2.55 and 5.80 ± 1.37 hr. No statistically significant difference was observed in any parameter indicating that kainic acid is not able to modify oral pharmacokinetics of CBZ and pharmacokinetic-pharmacodynamic studies may be carried out using two groups of animals, one for the pharmacodynamics and another for the pharmacokinetic evaluation. |
| Colaborador(es) u otros Autores: | Miriam del Carmen Carrasco-Portugal Alfonso Alfaro-Rodríguez Norma Labra-Ruiz Rosa Soriano-Rosales Francisco J. Flores-Murrieta Fructuoso Ayala-Guerrero |
| Fecha de publicación : | 2007 |
| Tipo de publicación: | Artículo |
| Formato: | |
| Fuente: | Proceedings of the Western Pharmacology Society 50(1):67-68 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2561 |
| Idioma: | eng |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.